Walter Public Investments Inc. Purchases 10,920 Shares of Novo Nordisk A/S (NYSE:NVO)

Walter Public Investments Inc. lifted its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 5.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 209,977 shares of the company's stock after buying an additional 10,920 shares during the period. Novo Nordisk A/S comprises about 2.7% of Walter Public Investments Inc.'s holdings, making the stock its 18th largest position. Walter Public Investments Inc.'s holdings in Novo Nordisk A/S were worth $14,581,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of NVO. Strategic Investment Solutions Inc. IL grew its stake in Novo Nordisk A/S by 2,727.3% in the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares during the period. Copeland Capital Management LLC grew its stake in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares during the period. North Capital Inc. bought a new stake in Novo Nordisk A/S in the first quarter worth about $27,000. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S in the fourth quarter worth about $29,000. Finally, Transce3nd LLC bought a new stake in Novo Nordisk A/S in the fourth quarter worth about $33,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

NVO traded down $2.43 on Friday, hitting $68.58. The company's stock had a trading volume of 2,727,186 shares, compared to its average volume of 7,288,619. The company's 50 day simple moving average is $70.36 and its 200-day simple moving average is $75.21. The firm has a market cap of $306.21 billion, a P/E ratio of 20.31, a price-to-earnings-growth ratio of 1.36 and a beta of 0.64. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $143.49. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The company had revenue of $11.87 billion for the quarter. Analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on NVO shares. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Saturday, June 14th. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. BMO Capital Markets reissued a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Finally, BNP Paribas assumed coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They issued an "underperform" rating on the stock. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.